All In Biotech

Drug Trial Radar · NCT03015909

Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device

Last checked: Nov 20, 2026Latest source record: Jan 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

116

Actual

Start

Aug 11, 2016

Primary completion

Dec 21, 2017

Study completion Dec 21, 2017

Sponsor

Lead sponsor
LG Life SciencesIndustry
Sponsor type
Industry
First posted
Jan 10, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.

Conditions

  • Short Stature, Idiopathic
  • Infant, Small for Gestational Age
  • Growth Hormone Deficiency
  • Chronic Renal Failure
  • Turner Syndrome

Interventions

  • SomatropinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ease of use for EutropinPen Inj. against previous reusable device assessed by a questionnaire.Time frame: Day 57
  2. Preference for EutropinPen Inj. against previous reusable device assessed by a questionnaire.Time frame: Day 57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ajou university hospital

    Suwon, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.